Olesoxime

Olesoxime

SCHEMBL1010552

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4=C/C(=N\O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATIC P31939 1/20 0.66
NPC1L1 Q9UHC9 3/20 0.61
USP2 O75604 3/20 0.58
RORC P51449 3/20 0.58
CYP46A1 Q9Y6A2 2/20 0.58
LMNA P02545 1/20 0.58
ABCB1 P08183 1/20 0.58
OSBP P22059 1/20 0.58
OSBP2 Q969R2 1/20 0.58
PTPN1 P18031 1/20 0.57
SRD5A1 P18405 3/20 0.54
CYP17A1 P05093 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MAPT P10636 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
FNTA P49354 1/20 0.52
FNTB P49356 1/20 0.52
RORA P35398 3/20 0.52
MEN1 O00255 1/20 0.52
ALOX15 P16050 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Olesoxime SCHEMBL19668134 1.00 ATIC (0.66) ATICNPC1L1USP2RORCCYP46A1
Olesoxime SCHEMBL1010553 1.00 ATIC (0.66) ATICNPC1L1USP2RORCCYP46A1
Olesoxime SCHEMBL18870340 1.00 ATIC (0.66) ATICNPC1L1USP2RORCCYP46A1
Olesoxime SCHEMBL19236075 1.00 ATIC (0.66) ATICNPC1L1USP2RORCCYP46A1
Olesoxime SCHEMBL19668133 1.00 ATIC (0.66) ATICNPC1L1USP2RORCCYP46A1
Olesoxime SCHEMBL19668128 1.00 ATIC (0.66) ATICNPC1L1USP2RORCCYP46A1
SCHEMBL20787615 0.91 ATIC (0.67) ATICNPC1L1USP2RORCCYP46A1
SCHEMBL20787613 0.91 ATIC (0.67) ATICNPC1L1USP2RORCCYP46A1
SCHEMBL20787612 0.91 ATIC (0.67) ATICNPC1L1USP2RORCCYP46A1
SCHEMBL20787614 0.91 ATIC (0.67) ATICNPC1L1USP2RORCCYP46A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160339041-A1 LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE TROPHOS (FR) 2016-11-24 US claimed
US-9320745-B2 Use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug TROPHOS (FR) 2016-04-26 US claimed
US-20150056269-A1 LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE TROPHOS (FR) 2015-02-26 US claimed
US-8575138-B2 Method for providing neuroprotection TROPHOS (FR) 2013-11-05 US claimed
US-8354395-B2 Method for providing neuroprotection from spinal muscular atrophy TROPHOS (FR) 2013-01-15 US claimed
US-20120316141-A1 METHOD FOR PROVIDING NEUROPROTECTION FROM SPINAL MUSCULAR ATROPHY TROPHOS (FR) 2012-12-13 US claimed
US-20120309721-A1 METHOD FOR PROVIDING NEUROPROTECTION TROPHOS (FR) 2012-12-06 US claimed
US-8283341-B2 Use as medicaments of derivatives of cholest-4-en-3-one, pharmaceutical compositions containing them, novel derivatives and their preparation process TROPHOS (FR) 2012-10-09 US claimed
EP-2001483-B1 USE OF CHOLEST-4-ENE-3-ONE DERIVATIVES TO OBTAIN A CYTOPROTECTIVE MEDICINE TROPHOS (FR) 2011-01-05 EP claimed
US-7858603-B2 neuroprotectants such as 1,4-cholestadien-3-one oxime, used for the treatment of neurodegenerative diseases TROPHOS (FR) 2010-12-28 US claimed
US-20100310674-A1 NOVEL COMPOSITION FOR TREATING THE SIDE EFFECTS OF ANTICANCER TREATMENTS TROPHOS (FR) 2010-12-09 US claimed
US-20100267680-A1 USE OF AT LEAST ONE OXIME DERIVATIVE OF CHOLEST-4-EN-3-ONE AS ANTIOXIDANTS TROPHOS (FR) 2010-10-21 US claimed
US-20100216752-A1 USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS TROPHOS (FR) 2010-08-26 US claimed
US-20100099652-A1 NOVEL COMPOSITION BASED ON CHOLEST-4-EN-3-ONE OXIME TROPHOS (FR) 2010-04-22 US claimed
US-20090186863-A1 USE OF CHOLEST-4-EN-3-ONE DERIVATIVES FOR OBTAINING A CYTOPROTECTIVE DRUG TROPHOS (FR) 2009-07-23 US claimed
US-20060217358-A1 Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof TROPHOS (FR) 2006-09-28 US claimed
CN-119118926-A KV7 channel activator compositions and methods of use 诺普生物科学有限责任公司 2024-12-13 CN disclosed
CN-118955402-A KV7 channel activator compositions and methods of use 诺普生物科学有限责任公司 2024-11-15 CN disclosed
WO-2008036410-A2 METHODS AND COMPOSITIONS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) MEDIVATION NEUROLOGY, INC. (US) 2008-03-27 WO disclosed
US-20060217358-A1 Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof TROPHOS (FR) 2006-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267680-A1 USE OF AT LEAST ONE OXIME DERIVATIVE OF CHOLEST-4-EN-3-ONE AS ANTIOXIDANTS ACOX3, GSTO1, GPX4 ATIC 3690/4885NPC1L1 80/4885USP2 2161/4885
US-20100099652-A1 NOVEL COMPOSITION BASED ON CHOLEST-4-EN-3-ONE OXIME CETP, ELOVL3, MTTP ATIC 4878/4885NPC1L1 72/4885USP2 3400/4885
US-20160339041-A1 LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE LIPA, NPC1L1, CETP ATIC 4085/4885NPC1L1 2/4885USP2 1496/4885
US-20100216752-A1 USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS CYP27A1, NLN, NPC1 ATIC 4625/4885NPC1L1 25/4885USP2 3916/4885
US-20120309721-A1 METHOD FOR PROVIDING NEUROPROTECTION BDNF, NLN, DCX ATIC 3135/4885NPC1L1 1941/4885USP2 3370/4885
US-20120316141-A1 METHOD FOR PROVIDING NEUROPROTECTION FROM SPINAL MUSCULAR ATROPHY SMN1; SMN2, BDNF, SOD1 ATIC 3546/4885NPC1L1 3403/4885USP2 2880/4885
US-20150056269-A1 LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE LIPA, NPC1L1, CETP ATIC 4085/4885NPC1L1 2/4885USP2 1496/4885
US-20090186863-A1 USE OF CHOLEST-4-EN-3-ONE DERIVATIVES FOR OBTAINING A CYTOPROTECTIVE DRUG NPC1, CYP27A1, NPC1L1 ATIC 4835/4885NPC1L1 3/4885USP2 2589/4885
US-20060217358-A1 Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof CYP46A1, NR1H4, CYP27A1 ATIC 3537/4885NPC1L1 28/4885USP2 3959/4885
US-20100310674-A1 NOVEL COMPOSITION FOR TREATING THE SIDE EFFECTS OF ANTICANCER TREATMENTS HCCS, CYP27A1, CETP ATIC 4720/4885NPC1L1 38/4885USP2 2933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.